[go: up one dir, main page]

PE20091376A1 - Derivados de fenilamino como moduladores de beta-amiloide - Google Patents

Derivados de fenilamino como moduladores de beta-amiloide

Info

Publication number
PE20091376A1
PE20091376A1 PE2009000020A PE2009000020A PE20091376A1 PE 20091376 A1 PE20091376 A1 PE 20091376A1 PE 2009000020 A PE2009000020 A PE 2009000020A PE 2009000020 A PE2009000020 A PE 2009000020A PE 20091376 A1 PE20091376 A1 PE 20091376A1
Authority
PE
Peru
Prior art keywords
alkyl
phenyl
phenylamine
beta
benzothiazol
Prior art date
Application number
PE2009000020A
Other languages
English (en)
Inventor
Karlheinz Baumann
Alexander Flohr
Erwin Goetschi
Helmut Jacobsen
Synese Jolidon
Thomas Luebbers
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PE20091376A1 publication Critical patent/PE20091376A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D277/82—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/113—Spiro-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

REFERIDA A UN COMPUESTO DERIVADO DE FENILAMINO DE FORMULA (I), DONDE R1 ES -C(O)O-ALQUILO C1-C7, CIANO O HETEROARILO DE 5 A 6 MIEMBROS OPCIONALMENTE SUSTITUIDO CON R'; R' ES HALOGENO, ALQUILO C1-C7, ALCOXI C1-C7, ENTRE OTROS; R2 ES H, ALCOXI C1-C7, ALQUILO C1-C7, ENTRE OTROS; R3 ES -(CH2)n-C(O)O-ALQUILO C1-C7, ALQUILO C1-C7, ENTRE OTROS; R4 ES H, ALQUILO C1-C7, HIDROXI, ENTRE OTROS; Y ES UN ENLACE, -O-, -CH2-, -CH2-CH2-, ENTRE OTROS; R ES H, ALQUILO C1-C7, C(O)O-ALQUILO C1-C7, ENTRE OTROS; n ES 0 O 1. SON COMPUESTOS PREFERIDOS: (4-FENIL-4,5,6,7-TETRAHIDRO-BENZOTIAZOL-2-IL)-(4-PIRIDIN-4-ILFENIL)AMINA, (3-METOXI-4-OXAZOL-5-IL-FENIL)-(4-FENIL-4,5,6,7-TETRAHIDRO-BENZOTIAZOL-2-IL)-AMINA, [3-METOXI-4-(4-METIL-IMIDAZOL-1-IL)-FENIL]-[4-(4-TRIFLUORMETOXI-FENIL)-4,5,6,7-TETRAHIDRO-BENZOTIAZOL-2-IL]-AMINA, ENTRE OTROS. TAMBIEN ESTA REFERIDA A UN METODO DE PREPARACION Y A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON MODULADORES DE BETA-AMILOIDE Y SON UTILES EN EL TRATAMIENTO DE LA ENFERMEDAD DE ALZHEIMER, ENTRE OTRAS
PE2009000020A 2008-01-11 2009-01-08 Derivados de fenilamino como moduladores de beta-amiloide PE20091376A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP08150173 2008-01-11

Publications (1)

Publication Number Publication Date
PE20091376A1 true PE20091376A1 (es) 2009-09-25

Family

ID=40429771

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2009000020A PE20091376A1 (es) 2008-01-11 2009-01-08 Derivados de fenilamino como moduladores de beta-amiloide

Country Status (18)

Country Link
US (1) US7923450B2 (es)
EP (1) EP2231629B1 (es)
JP (1) JP5306373B2 (es)
KR (1) KR101244517B1 (es)
CN (1) CN101910142B (es)
AR (1) AR070130A1 (es)
AT (1) ATE535515T1 (es)
AU (1) AU2009203773B2 (es)
BR (1) BRPI0906799A2 (es)
CA (1) CA2703824C (es)
CL (1) CL2009000023A1 (es)
ES (1) ES2375919T3 (es)
IL (1) IL205023A (es)
PE (1) PE20091376A1 (es)
RU (1) RU2010132728A (es)
TW (1) TW200934489A (es)
WO (1) WO2009087127A1 (es)
ZA (1) ZA201003814B (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0821141A2 (pt) * 2007-12-21 2015-06-16 Hoffmann La Roche Derivados de heteroarila como antagonistas do receptor de orexina
US7923450B2 (en) 2008-01-11 2011-04-12 Hoffmann-La Roche Inc. Modulators for amyloid beta
MX2010008700A (es) * 2008-02-22 2010-08-30 Hoffmann La Roche Moduladores de beta-amiloide.
EP2334665B1 (en) * 2008-10-09 2013-07-10 F. Hoffmann-La Roche AG Modulators for amyloid beta
AU2009311756B2 (en) * 2008-11-06 2012-05-03 Astrazeneca Ab Modulators of amyloid beta.
CN102209537A (zh) * 2008-11-10 2011-10-05 弗·哈夫曼-拉罗切有限公司 杂环γ分泌酶调节剂
TW201030002A (en) 2009-01-16 2010-08-16 Bristol Myers Squibb Co Bicyclic compounds for the reduction of beta-amyloid production
US8637525B2 (en) 2009-07-31 2014-01-28 Bristol-Myers Squibb Company Compounds for the reduction of beta-amyloid production
TWI468402B (zh) * 2009-07-31 2015-01-11 必治妥美雅史谷比公司 降低β－類澱粉生成之化合物
US20110190269A1 (en) * 2010-02-01 2011-08-04 Karlheinz Baumann Gamma secretase modulators
US8486967B2 (en) * 2010-02-17 2013-07-16 Hoffmann-La Roche Inc. Heteroaryl substituted piperidines
AU2011239966B2 (en) 2010-04-16 2014-05-08 Ac Immune S.A. Novel compounds for the treatment of diseases associated with amyloid or amyloid-like proteins
TW201206946A (en) * 2010-07-15 2012-02-16 Bristol Myers Squibb Co Compounds for the reduction of beta-amyloid production
US20120122843A1 (en) * 2010-11-11 2012-05-17 Astrazeneca Ab Compounds and Their Use for Treatment of Amyloid Beta-Related Diseases
AR084516A1 (es) * 2010-12-22 2013-05-22 Merz Pharma Gmbh & Co Kgaa Moduladores de receptores de glutamato metabotropicos
ES2602794T3 (es) 2011-03-31 2017-02-22 Pfizer Inc Piridinonas bicíclicas novedosas
US9206195B2 (en) 2011-08-09 2015-12-08 Boehringer Ingelheim International Gmbh Dihydrothienopyrimidines
UA110688C2 (uk) 2012-09-21 2016-01-25 Пфайзер Інк. Біциклічні піридинони
JP6396438B2 (ja) 2013-06-04 2018-09-26 アクチュラム・ライフ・サイエンス・アクチエボラーグ トリアゾール化合物およびガンマセクレターゼモジュレーターとしてのその使用
WO2014195321A1 (en) 2013-06-04 2014-12-11 Acturum Life Science AB Triazole compounds and their use as gamma secretase modulators
NO3004079T3 (es) 2013-06-04 2018-06-16
DK3253755T3 (da) 2015-02-03 2020-09-28 Pfizer Hidtil ukendte cyclopropabenzofuranyl-pyridopyrazindioner
WO2017158151A1 (en) 2016-03-18 2017-09-21 Savira Pharmaceuticals Gmbh Pyrimidone derivatives and their use in the treatment, amelioration or prevention of a viral disease
CN109311878B (zh) 2016-06-27 2022-05-24 豪夫迈·罗氏有限公司 作为γ-分泌酶调节剂的三唑并吡啶类化合物
GB201916561D0 (en) 2019-11-14 2020-01-01 Vib Vzw Gamma-secretase inhibitor screening assay
US20250101026A1 (en) * 2022-01-25 2025-03-27 Board Of Regents Of The University Of Nebraska Functionalized Allopurinol Derivatives for Treatment of Alzheimer’s Disease

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG47583A1 (en) 1986-01-13 1998-04-17 American Cyanamid Co 4,5,6-Substituted-n- (substituted-phenyl) -2- pyrimidinamines
US5387595A (en) 1992-08-26 1995-02-07 Merck & Co., Inc. Alicyclic compounds as tachykinin receptor antagonists
ATE288904T1 (de) 1998-06-18 2005-02-15 Bristol Myers Squibb Co Durch kohlenstoff substituierte aminothiazole als inhibitoren von zyclin-abhägigen kinasen
EP1126843A4 (en) 1998-10-29 2005-06-15 Bristol Myers Squibb Co AMINO-CELL DERIVATIVE COMPOUNDS INHIBITORS OF ENZYME IMPDH
SE9803773D0 (sv) 1998-11-05 1998-11-05 Astra Pharma Prod Compounds
GB9914258D0 (en) 1999-06-18 1999-08-18 Celltech Therapeutics Ltd Chemical compounds
EP1246823A1 (en) 1999-12-28 2002-10-09 Pharmacopeia, Inc. Pyrimidine and triazine kinase inhibitors
US20030176454A1 (en) * 2000-05-15 2003-09-18 Akira Yamada N-coating heterocyclic compounds
MXPA03011706A (es) 2001-06-28 2004-03-19 Smithkline Beecham Plc Derivados de n-aroil-amina ciclica como antagonistas del receptor de orexina.
WO2003040141A1 (en) 2001-09-28 2003-05-15 Bayer Pharmaceuticals Corporation Oxazolyl-phenyl-2,4-diamino-pyrimidine compounds and methods for treating hyperproliferative disorders
WO2003095448A1 (en) 2002-05-06 2003-11-20 Bayer Pharmaceuticals Corporation Pyridinyl amino pyrimidine derivatives useful for treating hyper-proliferative disorders
US7163928B2 (en) 2003-02-03 2007-01-16 Cv Therapeutics, Inc. Partial and full agonists of A1 adenosine receptors
ATE396731T1 (de) 2003-03-25 2008-06-15 Vertex Pharma Thiazole zur verwendung als inhibitoren von protein-kinasen
MXPA05012281A (es) * 2003-05-14 2006-05-19 Torreypines Therapeutics Inc Compuestos y uso de los mismos en la modulacion beta amiloide.
DE602004032446D1 (de) 2003-08-07 2011-06-09 Rigel Pharmaceuticals Inc 2,4-pyrimidindiamin-verbindungen und verwendungen als antiproliferative mittel
EP1757591A4 (en) * 2004-05-26 2010-05-05 Eisai R&D Man Co Ltd ZIMTSÄUREAMIDVERBINDUNG
EP1773795A1 (en) * 2004-07-22 2007-04-18 F.Hoffmann-La Roche Ag Substituted benzothiazoles
CN101098698A (zh) 2004-12-01 2008-01-02 德福根有限公司 与离子通道尤其是Kv家族离子通道相互作用的5-羧酰胺基取代的噻唑衍生物
US20060241038A1 (en) 2005-04-20 2006-10-26 Eisai Co., Ltd. Therapeutic agent for Abeta related disorders
CN101163706A (zh) 2005-04-21 2008-04-16 贝林格尔·英格海姆国际有限公司 用于治疗炎性疾病的二氢噻吩并嘧啶
HUE028987T2 (en) 2005-11-01 2017-01-30 Targegen Inc Bi-aryl meta-pyrimidine inhibitors of kinases
EP1953151A4 (en) 2005-11-18 2010-06-02 Eisai R&D Man Co Ltd SALTS FROM A CYNNAMIDE COMPOUND OR SOLVATE THEREOF
EP1950211A4 (en) 2005-11-18 2011-08-31 Eisai R&D Man Co Ltd PROCESS FOR PREPARING A CINEMA ACID AMID DERIVATIVE
US20070117839A1 (en) * 2005-11-24 2007-05-24 Eisai R&D Management Co., Ltd. Two cyclic cinnamide compound
MY144960A (en) * 2005-11-24 2011-11-30 Eisai R&D Man Co Ltd Morpholine type cinnamide compound
AR059955A1 (es) 2006-03-09 2008-05-14 Eisai R&D Man Co Ltd Compuestos policiclicos no peptidicos, medicamentos que los contienen, y usos para prevenir o tratar enfermedades causadas por la produccion de beta amiloide
TWI378091B (en) * 2006-03-09 2012-12-01 Eisai R&D Man Co Ltd Multi-cyclic cinnamide derivatives
TW200808739A (en) * 2006-04-06 2008-02-16 Novartis Vaccines & Diagnostic Quinazolines for PDK1 inhibition
US20100105904A1 (en) 2006-05-19 2010-04-29 Teiji Kimura Urea type cinnamide derivative
EP2019094A4 (en) 2006-05-19 2011-01-05 Eisai R&D Man Co Ltd HETEROCYCLIC TYPE CINNAMIDE DERIVATIVE
JP2009184924A (ja) 2006-05-31 2009-08-20 Eisai R & D Management Co Ltd 生物学的試薬用化合物
WO2008006103A2 (en) 2006-07-07 2008-01-10 Wyeth Nogo receptor functional motifs, peptide mimetics, and mutated functional motifs related thereto, and methods of using the same
AR062095A1 (es) 2006-07-28 2008-10-15 Eisai R&D Man Co Ltd Profarmaco de compuesto cinamida
DE602007012142D1 (en) 2006-12-01 2011-03-03 Actelion Pharmaceuticals Ltd 3-heteroaryl (amino bzw. amido)-1- (biphenyl bzw. phenylthiazolyl) carbonylpiperdinderivate als orexinrezeptor-inhibitoren
DE102007010801A1 (de) 2007-03-02 2008-09-04 Bayer Cropscience Ag Diaminopyrimidine als Fungizide
CA2686754C (en) 2007-05-11 2014-10-28 F. Hoffmann-La Roche Ag Hetarylanilines as modulators for amyloid beta
CA2698511C (en) 2007-09-04 2016-10-11 The Scripps Research Institute Substituted pyrimidinyl-amines as protein kinase inhibitors
BRPI0821141A2 (pt) * 2007-12-21 2015-06-16 Hoffmann La Roche Derivados de heteroarila como antagonistas do receptor de orexina
US7923450B2 (en) 2008-01-11 2011-04-12 Hoffmann-La Roche Inc. Modulators for amyloid beta
MX2010008700A (es) * 2008-02-22 2010-08-30 Hoffmann La Roche Moduladores de beta-amiloide.

Also Published As

Publication number Publication date
JP2011509272A (ja) 2011-03-24
BRPI0906799A2 (pt) 2015-07-14
IL205023A (en) 2013-11-28
KR20100090810A (ko) 2010-08-17
EP2231629B1 (en) 2011-11-30
AR070130A1 (es) 2010-03-17
EP2231629A1 (en) 2010-09-29
WO2009087127A1 (en) 2009-07-16
ES2375919T3 (es) 2012-03-07
US20090181965A1 (en) 2009-07-16
CA2703824A1 (en) 2009-07-16
ZA201003814B (en) 2011-02-23
IL205023A0 (en) 2010-11-30
JP5306373B2 (ja) 2013-10-02
AU2009203773A1 (en) 2009-07-16
CA2703824C (en) 2016-06-07
CL2009000023A1 (es) 2010-05-07
US7923450B2 (en) 2011-04-12
CN101910142B (zh) 2013-07-10
TW200934489A (en) 2009-08-16
KR101244517B1 (ko) 2013-03-18
ATE535515T1 (de) 2011-12-15
RU2010132728A (ru) 2012-02-20
AU2009203773B2 (en) 2013-04-18
CN101910142A (zh) 2010-12-08

Similar Documents

Publication Publication Date Title
PE20091376A1 (es) Derivados de fenilamino como moduladores de beta-amiloide
PE20091834A1 (es) Compuestos de 2-imino-3-metilpirrolopirimidinona tiofenilo-sustituida como inhibidores de bace-1 y composiciones que los contienen
PE20060777A1 (es) Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
PE20130602A1 (es) Derivados de 6-cicloalquil-1,5-dihidro-pirazolo(3,4-d)pirimidin-4-onas y su uso como inhibidores de pde9a
PE20090276A1 (es) Compuestos derivados de imidazoquinolina como moduladores de tlr7
CY1116885T1 (el) Υποκατεστημενα παραγωγα κυκλοεξυλομεθυλιου
PE20110061A1 (es) Derivados de diamino-piridina, pirimidina y piridazina como moduladores del receptor h4 de histamina
PE20061297A1 (es) Compuestos derivados de cromano y cromeno moduladores del receptor de serotonina 5-ht2c
PE20091621A1 (es) Derivados de amina como moduladores de la actividad de tlr y composiciones que los contienen
PE20080948A1 (es) Derivados de imidazol como moduladores de la senda de hedgehog
DE602006006850D1 (de) Als modulatoren von dopamin-d3-rezeptoren geeignete azabicyclo-(3,1,0)-hexan-derivate
UY30316A1 (es) Derivados sustituidos de benzamidas, nicotinamidas, propanamidas, acetamidas y carboxamidas n-(2-(piperidin-1-ilmetil)ciclohexil)sustituidas, procesos de preparacion, composiciones conteniéndolos y aplicaciones
PE20140968A1 (es) Derivados de benzamida sustituida
PE20061490A1 (es) Derivados de ciclohexanosulfonilo como inhibidores del transportador de glicina glyt1
DE602007001463D1 (de) Pyrimidin-, chinazolin-, pteridin- und triazinderivate
PE20081368A1 (es) Derivados de azabiciclo[4.1.0]heptano como inhibidores de la recaptacion de serotonina, dopamina y norepinefrina
PE20070491A1 (es) Compuestos derivados de 9-azabiciclo[3.3.1]nonano como inhibidores de la recaptacion de neurotransmisores de monoamina
ATE430744T1 (de) Thiazolylpiperidin-derivate nützlich als h3 rezeptor modulatoren
PE20060625A1 (es) Derivados de benzazepina como antagonistas y/o agonistas del receptor h3 de histamina
NO20082214L (no) 1,1-Diokso-tiomorfolinyl-indolyl-metanonderivater for anvendelse som H3-modulatorer
PE20091182A1 (es) DERIVADOS DE IMIDAZO[1,2-a]PIRIDIN-2-CARBOXAMIDAS, SU PREPARACION Y SU APLICACION EN TERAPEUTICA
ECSP088257A (es) Derivados de amida
GB0507601D0 (en) Compounds
PE20080898A1 (es) Derivados de quinolina como moduladores de 5-ht5a
EA200800810A1 (ru) Соль глюкуроновой кислоты и соединения пиперазина

Legal Events

Date Code Title Description
FD Application declared void or lapsed